Fintel on MSN7 天
Maxim Group Upgrades Moleculin Biotech (MBRX)
Fintel reports that on March 25, 2025, Maxim Group upgraded their outlook for Moleculin Biotech (NasdaqCM:MBRX) from Hold to ...